All members of the Src gene family of tyrosine kinases are characterized by a carboxy terminal domain tyrosine which is highly phosphorylated in the inactive form of the enzyme and phosphorylated to a much lesser extent when the enzyme is active. In the case of Src p60, Y527 is this tyrosine; however, a mutant form of c-Src in which Y527 is replaced by phenylalanine is transforming and displays 5- to 10-fold elevated kinase activity compared to its normal counterpart. Csk has been identified as a Src-related tyrosine kinase having both SH2 and SH3 domains and a catalytic domain but lacking sequences amino terminal to the SH3 domain as well as carboxy terminal regulatory sequences. Csk phosphorylates Src on Y527 and also downregulates Lyn, Fyn and Lck by tyrosine phosphorylation of carboxy terminal regulatory sites.
|Target Protein||CSK Ser364|
|Source||KLH conjugated synthetic phosphopeptide derived from human CSK around the phosphorylation site of Ser364|
|Purification||Purified by Protein A.|
|Storage||Aqueous buffered solution containing 100ug/ml BSA, 50% glycerol and 0.09% sodium azide. Store at 4°C for 12 months.|
|Synonyms||CSKphospho S364; p-CSKphospho S364; C SRC; C SRC kinase; C src Tyrosine Kinase; C-SRC kinase; c-src tyrosine kinase; Csk A; CSK; CSK_HUMAN; CYTOPLASMIC TYROSINE KINASE; EC 22.214.171.124; MGC112926; MGC117393; MGC154049; P60 Src; Protein tyrosine kinase CYL; Protein-tyrosine kinase CYL; Proto oncogene tyrosine protein kinase; Tyrosine protein kinase CSK; Tyrosine-protein kinase CSK; zgc:154049.|